Option Care Health (OPCH) Q2 2024 earnings summary

Executive summary

• Net revenue for Q2 2024 increased 14.8% year-over-year to $1.23 billion, driven by organic growth in both acute and chronic therapies, with strong contributions from new limited distribution and rare/orphan therapies.

• Net income for Q2 2024 was $53.0 million, down 53.6% from $114.4 million in Q2 2023, which included a one-time Amedisys merger termination payment.

• Successfully navigated major challenges, including a disruptive cyberattack and supply chain disruptions, with operational recovery and claims processing largely completed by quarter-end.

• Maintained uninterrupted patient onboarding and service, leveraging innovative workarounds and process modifications.

• Continued to engage with the investment community and reinforced the value of a diversified therapeutic base.

Financial highlights

• Gross profit was $249.4 million (20.3% margin), slightly down from $250.8 million (23.5% margin) in Q2 2023 due to higher cost therapies and less favorable procurement dynamics.

• Adjusted EBITDA reached $108.4 million, down 1.5% year-over-year, representing 8.8% of revenue.

• Earnings per share was $0.30, benefiting from share repurchases, compared to $0.63 in Q2 2023.

• Cash flow from operations for Q2 2024 was $195.7 million, up from $169.5 million in Q2 2023.

• Cash and cash equivalents at quarter-end were $376.9 million.

Outlook and guidance

• Full-year 2024 net revenue expected between $4.75 billion and $4.85 billion.

• Adjusted EBITDA guidance raised to $435–$450 million.

• Cash flow from operations projected at least $300 million for the year.

• Net interest expense forecasted at $55 million to $60 million; effective tax rate 26%-28%.